Cas No.:	47931-85-1
Chemical Name:	Calcitonin (salmon)
Synonyms:	Calcitonin (salmon);Calcitonin (salmon I);thyrocalcitonin salmon;H-Cys-Ser-Asn-Leu-Ser-Thr-Cys-Val-Leu-Gly-Lys-Leu-Ser-Gln-Glu-Leu-His-Lys-Leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asn-Thr-Gly-Ser-Gly-Thr-Pro-NH2 (Disulfide bond);Calcitonin salmon;Thyrocalcitonin;Salmon Calcitonin Acetate;Calcitonin (salMon) xAcetate;Calcitonin salmon Acetate;Calcitonin(Salmone) Acetate;Salmon calcitonin;calcimar;Calcitoran;cibacalcin;CYS-SER-ASN-LEU-SER-THR-CYS-VAL-LEU-GLY-LYS-LEU-SER-GLN-GLU-LEU-HIS-LYS-LEU-GLN-THR-TYR-PRO-ARG-THR-ASN-THR-GLY-SER-GLY-THR-PRO-NH2(DISULFIDE BRIDGE CYS1-CYS7);Salcatonin;Salcitonin;SALMON;Salmon Calcium;Salmotonin;tz-ct
SMILES:	CC(C[C@H](NC([C@@H](NC([C@@H]1CSSC[C@H](N)C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N1)=O)[C@H](O)C)=O)CO)=O)CC(C)C)=O)CC(N)=O)=O)CO)=O)=O)C(C)C)=O)C(NCC(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N2CCC[C@H]2C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(NCC(N[C@H](C(NCC(N[C@H](C(N3CCC[C@H]3C(N)=O)=O)[C@H](O)C)=O)=O)CO)=O)=O)[C@H](O)C)=O)CC(N)=O)=O)[C@H](O)C)=O)CCCNC(N)=N)=O)=O)CC4=CC=C(O)C=C4)=O)[C@H](O)C)=O)CCC(N)=O)=O)CC(C)C)=O)CCCCN)=O)CC5=CN=CN5)=O)CC(C)C)=O)CCC(O)=O)=O)CCC(N)=O)=O)CO)=O)CC(C)C)=O)CCCCN)=O)=O)C
Formula:	C145H240N44O48S2
M.Wt:	3431.85
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:	Calcitonin salmon, a calcium regulating hormone, is a dual-action amylin and calcitonin receptor agonist, could stimulate bone formation and inhibit bone resorption. Sequence: Cys-Ser-Asn-Leu-Ser-Thr-Cys-Val-Leu-Gly-Lys-Leu-Ser-Gln-Glu-Leu-His-Lys-Leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asn-Thr-Gly-Ser-Gly-Thr-Pro-NH2(Disulfide bridge: Cys1-Cys7).
In Vivo:	Oral Calcitonin salmon treatment dose-dependently attenuates fasting and non-fasted hyperglycaemia during the intervention period. At the end of the study period, oral Calcitonin salmon treatment by dose decreases diabetic hyperglycaemia by ~9 mM and reduces HbA1c levels by 1.7%. Furthermore, a pronounced reduction in glucose excursions is dose-dependently observed for oral Calcitonin salmon treatment during oral glucose tolerance test. In addition, oral Calcitonin salmon treatment sustains hyperinsulinaemia and attenuates hyperglucagonaemia and hypersecretion of total glucagon-like peptide-1 predominantly in the basal state. Lastly, oral Calcitonin salmon treatment dose-dependently improves pancreatic beta-cell function and beta-cell area at study end[1].
Animal Administration:	Rats[1] Male ZDF rats are treated with oral Calcitonin salmon (sCT: 0.5, 1.0 or 2 mg/kg) or oral vehicle twice daily from age 8 to 18 weeks. Zucker lean rats serve as control group. Fasting and non-fasted blood glucose, glycosylated haemoglobin (HbA1c) and levels of pancreas and incretin hormones are determined. Oral glucose tolerance test and i.p. glucose tolerance test were compared, and beta-cell area and function were evaluated[1].
References:	[1]. Feigh M, et al. Oral salmon calcitonin attenuates hyperglycaemia and preserves pancreatic beta-cell area and function in Zucker diabetic fatty rats. Br J Pharmacol. 2012 Sep;167(1):151-63.